In a patient undergoing percutaneous coronary intervention (PCI) with a normal left ventricular ejection fraction and no angina, arrhythmia, or hypertension, should chronic beta‑blocker therapy be initiated?

Beta-Blockers After PCI with Normal EF: Not Recommended for Routine Long-Term Use

In patients undergoing PCI with normal left ventricular ejection fraction (≥50%) and no other primary indication (no angina, arrhythmia, or hypertension), chronic beta-blocker therapy should NOT be routinely initiated or continued beyond 1 year, as it does not reduce major adverse cardiovascular events (MACE) or mortality.

Evidence-Based Recommendation Framework

Primary Guideline Position (2023)

The most recent 2023 AHA/ACC Chronic Coronary Disease Guideline 1, 2 fundamentally changed the approach to beta-blockers in this population:

• Class 3: No Benefit - Beta-blocker therapy is NOT beneficial in reducing MACE in patients with chronic coronary disease (CCD) without previous MI or LVEF ≤50%, in the absence of another primary indication (angina, arrhythmias, uncontrolled hypertension)

• Class 2b - It may be reasonable to reassess the indication for long-term (>1 year) beta-blocker therapy in patients initiated on beta-blockers for previous MI who now have LVEF >50% and no ongoing angina, arrhythmias, or uncontrolled hypertension

This represents a major departure from older guidelines that recommended routine beta-blocker use.

Supporting Contemporary Evidence

The REDUCE-AMI trial (2024) 3 provides the highest-quality, most recent evidence directly addressing this question:

• 5,020 patients with acute MI and LVEF ≥50% randomized to beta-blocker vs. no beta-blocker
• Median 3.5-year follow-up in the modern PCI era
• Primary endpoint (death or new MI): 7.9% with beta-blockers vs. 8.3% without (HR 0.96,95% CI 0.79-1.16; p=0.64)
• No benefit for any secondary endpoint including cardiovascular death, MI, heart failure hospitalization, or atrial fibrillation
• Safety profile comparable between groups

Multiple contemporary meta-analyses 4, 5, 6 confirm these findings, showing no reduction in MACE when LVEF ≥50%.

Clinical Decision Algorithm

Step 1: Assess Ejection Fraction

• LVEF ≥50% → Proceed to Step 2
• LVEF 40-49% → Consider beta-blocker (observational data suggest possible benefit 4, 5)
• LVEF <40% → Strongly recommend beta-blocker (Class I indication) 7

Step 2: Identify Other Primary Indications

Continue/initiate beta-blockers ONLY if:

• Symptomatic angina requiring antianginal therapy
• Arrhythmias (atrial fibrillation with rate control needs, ventricular arrhythmias)
• Uncontrolled hypertension requiring beta-blocker
• Heart failure symptoms
• Within 1 year of acute MI (Class I for 3 years per older guidelines 7, though 2023 guidelines suggest reassessment after 1 year 1)

Step 3: If No Other Indications Present

Discontinue or do not initiate chronic beta-blocker therapy in patients with LVEF ≥50% post-PCI

Important Nuances and Caveats

The Evolution of Evidence

Older guidelines (2006-2014) 8, 9, 7 recommended:

• Class I: Beta-blockers for 3 years after MI/ACS with normal LV function
• Class IIb: Beta-blockers for all patients with coronary disease

These recommendations were based on trials from the pre-reperfusion era (1980s-1990s) when:

• Infarct sizes were larger
• PCI was not routinely performed
• Modern antiplatelet therapy, high-intensity statins, and ACE inhibitors were not standard

Contemporary Practice Context

The 2023 guideline shift 1, 2 reflects:

• Universal early PCI with smaller infarct sizes
• Comprehensive guideline-directed medical therapy (GDMT)
• Modern biomarker-based MI diagnosis (detecting smaller events)
• Real-world evidence showing no benefit in preserved EF populations 3, 10, 11

The "Mildly Reduced" EF Gray Zone (40-49%)

This subgroup shows conflicting evidence:

• Observational data suggest possible 25% relative risk reduction 4, 5
• However, this comes from non-randomized studies with potential confounding
• Reasonable approach: Consider beta-blocker in LVEF 40-49%, but recognize evidence is weaker than for LVEF <40%

Preferred Beta-Blockers When Indicated

If beta-blockers ARE indicated (LVEF <50% or other primary indication), use evidence-based agents 1, 7:

• Carvedilol
• Metoprolol succinate (not tartrate)
• Bisoprolol

These three have proven mortality reduction in heart failure trials.

Common Clinical Pitfalls

1. Inertia from older guidelines - Many clinicians continue reflexive beta-blocker prescribing post-PCI based on outdated recommendations

2. Failure to reassess - Patients started on beta-blockers acutely often remain on them indefinitely without reassessment of indication

3. Misapplying heart failure data - The strong mortality benefit in LVEF <40% does NOT extend to preserved EF populations

4. Ignoring patient burden - Beta-blockers cause fatigue, exercise intolerance, sexual dysfunction, and bradycardia without providing benefit in this population

5. Confusing antianginal with prognostic benefit - Beta-blockers may help angina symptoms but don't reduce events in preserved EF without angina

Bottom Line for Clinical Practice

For your patient undergoing PCI with normal EF and no angina, arrhythmia, or hypertension:

• Do NOT initiate chronic beta-blocker therapy
• If already on beta-blockers from acute phase, reassess indication at 1 year and strongly consider discontinuation
• Focus instead on proven therapies: high-intensity statin, antiplatelet therapy, ACE inhibitor/ARB if indicated, and SGLT2 inhibitor or GLP-1 agonist if diabetic
• Reserve beta-blockers for patients with specific indications where benefit is established

This recommendation prioritizes avoiding unnecessary medication burden while focusing on therapies that actually improve morbidity and mortality in this population 1, 2, 3.